Company: NCEL
Filing Date: 2025-03-31
Form Type: 6-K
Source: 0001213900-25-025839
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 6-K
Chunk 2
---
 commencement of trading on any trading day. The purchase price of the Common Shares that the
Company elects to sell to the Investor pursuant to the Purchase Agreement will be 95% of the volume weighted average price of the Common
Shares during the applicable purchase date on which the Company has timely delivered written notice to the Investor directing it to purchase
Common Shares under the Purchase Agreement.

<div align='center'>1</div>

In connection with the execution
of the Purchase Agreement, the Company agreed to issue a pre-funded warrant, or the Pre-Funded Warrant, to purchase $250,000 in Common
Shares to The Investor as consideration for its irrevocable commitment to purchase the Common Shares upon the terms and subject to the
satisfaction of the conditions set forth in the Purchase Agreement. The Purchase Agreement contains customary registration rights, representations,
warranties, conditions and indemnification obligations by each party. The representations, warranties and covenants contained in the Purchase
Agreements were made only for purposes of the Purchase Agreements and as of specific dates, were solely for the benefit of the parties
to such agreements and are subject to certain important limitations.

The Company has the right
to terminate the Purchase Agreement at any time after Commencement, at no cost or penalty, upon 10 days’ prior written notice. No
termination of the Purchase Agreement will affect the registration rights provisions contained within the Purchase Agreement, which will
survive any termination of the Purchase Agreement.

This report shall not constitute
an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.

The foregoing summary of the
Securities Purchase Agreement, the Registration Rights Agreement, the Purchase Agreement and the Pre-Funded Warrant do not purport to
be complete and are qualified in their entirety by reference to the Securities Purchase Agreement, Registration Rights Agreement, the
Purchase Agreement and the Pre-Funded Warrant which are attached as Exhibits 99.1, 99.2, 99.3 and 99.4 to this Report on Form 6-K and
are incorporated herein by reference.

Press Release

On March 31, 2025, the Company
issued a press release titled: “NLS Pharmaceutics and Kadimastem Announce Closing of $